Biotech Selects Almac's Interactive Response Platform

A global biotech will be migrating to its newest generation Interactive Response Technology (IRT), platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.

Almac Clinical Technologies, part of the Almac Group, has announced that a global biotechnology company will be migrating to its newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.  

Read the full release.